AstraZeneca Pharma India block deals, bulk deals and stake changes
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
Formerly Astra IDL
Last close ₹5,988.50down ₹112.50 (1.84%)BSE ₹5,988.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹6,101.00.
52-week range of traded prices to 23 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,971 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 88.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 17.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,11847.8% delivered
AstraZeneca Pharma India stake sales and purchases
All 3 disclosures on record.
Mar 2020
- AcquiredTejas B Trivedi alongwith PAC · promoter0.07% of the company18,478 sharesholds 5.04% after20 Mar 2020 · filed under the 5% rule · Open Market
Jan 2019
- SoldICICI Prudential Mutual Fund ( the Fund ) Under its various0.46% of the company1,15,578 sharesholds 3.11% after15 Jan 2019 · filed under the 2% rule
Sep 2015
- AcquiredICICI PRUDENTIAL MUTUAL FUND UNDER ITS VARIOUS SCHEMES0.80% of the company1,98,836 sharesholds 5.16% after3 Sep 2015 · filed under the 5% rule
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
AstraZeneca Pharma India block deals and bulk deals
None in the last 12 months, since 23 Oct 2025.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Monday 7 Oct 20241 firm · ₹99 Cr bought · ₹99 Cr soldNet sold ₹0.03 Cr
- Both waysGRAVITON RESEARCH CAPITAL LLPBought 1,25,166 at ₹7,884.41Sold 1,25,166 at ₹7,887.160.50% of the companyNet nil₹99 Cr bought
Monday 30 Sep 20241 firm · ₹99 Cr bought · ₹99 Cr soldNet sold ₹0.04 Cr
- Both waysGRAVITON RESEARCH CAPITAL LLPBought 1,27,119 at ₹7,802.00Sold 1,27,119 at ₹7,804.960.51% of the companyNet nil₹99 Cr bought
Tuesday 24 Sep 20241 firm · ₹98 Cr bought · ₹99 Cr soldNet sold ₹0.09 Cr
- Both waysGRAVITON RESEARCH CAPITAL LLPBought 1,31,308 at ₹7,499.17Sold 1,31,308 at ₹7,506.360.53% of the companyNet nil₹98 Cr bought
Monday 19 Sep 20224 firms · ₹25 Cr bought · ₹25 Cr soldNet nil
- SoldISHARES CORE EMERGING MARKETS MAURITIUS COBlock dealSold 74,097 at ₹3,152.550.30% of the company₹23 Cr
- BoughtISHARES CORE MSCI EMERGING MARKETS ETFBlock dealBought 74,097 at ₹3,152.550.30% of the company₹23 Cr
- SoldISHARES INDIA SC MAURITIUS COMPANYBlock dealSold 6,542 at ₹3,152.550.03% of the company₹2.06 Cr
- BoughtISHARES MSCI INDIA SMALL-CAP ETFBlock dealBought 6,542 at ₹3,152.550.03% of the company₹2.06 Cr
Wednesday 3 Apr 20191 firm · ₹0 bought · ₹25 Cr soldNet sold ₹25 Cr
- SoldICICI PRUDENTIAL MUTUAL FUND A/C VOLATILITY ADVANTAGE PLANSold 1,25,000 at ₹2,000.000.50% of the company₹25 Cr
Thursday 30 May 20132 firms · ₹11 Cr bought · ₹22 Cr soldNet sold ₹10 Cr
- SoldCROSSEAS CAPITAL SERVICES PRIVATE LIMITEDSold 1,26,180 at ₹845.63₹11 Cr
- Both waysCROSSEAS CAPITAL SERVICES PVT. LTD.Bought 1,31,291 at ₹844.46Sold 1,28,849 at ₹845.78Net +2,442 shares₹11 Cr bought
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 12 deals on record from 4 Jan 2004.